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Abstract
Background: Cadmium, a ubiquitous environmental pollutant, exhibits potential neurotoxic risk. Although
compelling evidence suggests cadmium accumulation has a role in the formation of amyloid-β plaques and
neurofibrillary tangles, which are the hallmarks of Alzheimer's disease (AD) pathogenesis, the supporting evidence
in humans is limited and conflicting. In this study, we investigated the association between blood cadmium levels
and AD mortality among older adults by analyzing the prospective data from the 1999–2004 Third National Health
and Nutrition Examination Survey (NHANES) and the Linked Mortality File.
Methods: The data were obtained from the 1999–2004 NHANES and the NHANES (1999–2004) Linked Mortality
File. A total of 4,064 participants aged ≥60 years old with available blood cadmium data and no other missing
information on their questionnaires at baseline were included in this study. AD was denoted as G30 based on
the ICD-10 underlying causes of death.
Results: Of the 4,064 participants, 51 subjects died as a result of AD. Compared with participants with low blood
cadmium levels (≤0.3 μg/L), those with high cadmium levels (>0.6 μg/L) exhibited a 3.83-fold (hazard ratio = 3.83;
95 % CI = 1.39–10.59) increased risk of AD mortality. In the Kaplan–Meier survival curves for cumulative AD mortality,
higher levels of blood cadmium showed marginally significant association with increased mortality at baseline and
in patients over 60 years of age (p = 0.0684).
Conclusions: We observed a significant association between blood cadmium levels and AD mortality among older
adults in the US. Our findings suggest that environmental exposure to cadmium may be a risk factor for AD.
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Background
Alzheimer’s disease (AD) is a progressive neurodegener-
ative disease that is characterized by the deposition of
amyloid-β (Aβ) plaques and neurofibrillary tangles in the
brain [1, 2]. The cause of AD is multifactorial and in-
volves genetic predisposition, advanced age, low educa-
tion, and health behaviors (i.e., smoking and physical
inactivity) [3]. There is strong consensus that environ-
mental pollutants are implicated in the pathogenesis of
AD, and that they play a role in the formation of amyl-
oid plaques and neuronal damage [4].
Cadmium is a ubiquitous environmental pollutant that
is released by various natural and anthropogenic activities
(i.e., mining, fossil fuel combustion, and the production of
batteries and pigments) in to the atmosphere [5]. Cad-
mium has received much attention because of adverse
health effects on the kidneys and the skeletal system and
its carcinogenic properties [6]. Compelling evidence
suggests that cadmium may also confer a neurotoxic risk
[7, 8]. Experimental studies have proposed that cadmium
can induce cell death and apoptotic morphological
changes in cerebral cortical neurons [9–11]. Human ex-
posure to cadmium is associated with slowing neurobe-
havioral performance and lower cognitive scores for
workers in an industry and also in the general population
[12–14]. Some authors reported increased body-burdens
of cadmium among AD patients relative to healthy indi-
viduals, [15–17], although reports are conflicting [15].
Given the neurological toxicity of cadmium and its
possible association with AD, we wanted to explore
whether environmental exposure to cadmium is a risk
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factor for AD. In this study, we investigated the associ-
ation between blood cadmium levels and AD mortality
among older adults by analyzing the prospective data
from the 1999–2004 Third National Health and Nutri-
tion Examination Survey and the Linked Mortality File.
Methods
Study population
We used data from the 1999–2004 NHANES and the
NHANES (1999–2004) Linked Mortality Public File
from the United States [18]. The latter was a follow-up
study of mortality that matched records from NHANES
with data in the National Death Index as of Dec. 31,
2011 [19]. The date and cause of death in the National
Death Index were derived from death certificates. The
NHANES Linked Mortality files are available in two-
year increments (e.g., NHANES 1999–2000, NHANES
2001–2002, and NHANES 2003–2004).
From the 1999–2004 NHANES data and the linked
morality file, we initially included 5,603 participants aged
≥60 years at the time of the initial survey. We excluded
868 older adults for whom blood cadmium levels or
causes of death recode were unavailable; we also ex-
cluded 671 participants who had missing data for other
variables. The cohort analysis presented in this study
was based on 4064 older adults in the 1999–2004
NHANES. This study's protocol was approved by the in-
stitutional review board of Seoul National University
Hospital (IRB No. E-1604-074-754).
Variable of interest
For the measurement of blood cadmium, whole blood
specimens were processed, stored, and shipped to the
Division of Environmental Health Laboratory Sciences,
National Center for Environmental Health, Centers for
Disease Control and Prevention for analysis. Blood
cadmium levels were measured by a PerkinElmer Model
SIMAA 6000 (PerkinElmer, Norwalk, CT) simultaneous
multi-element atomic absorption spectrometer with Zee-
man background correction. The analytical laboratory
followed extensive quality control procedures. Whole-
blood materials from the National Institute of Standards
and Technology Standard Reference Materials were used
for external calibration.
International Classification of Diseases 10th Revision
(ICD-10) codes were used for all causes of deaths, and
the code for AD was G30 based on the ICD-10 under-
lying causes of death.
Baseline covariates were obtained from the interview
data of the 1999–2004 NHANES and included age
(60–69, 70–79, and 80–89 yr), sex, ethnic background
(white, black, Hispanic or other), education (less than
high school, high school graduate, college or more),
family income (less than $20,000 or $20,000 or more),
smoking status (current, former, or never), serum co-
tinine (≤0.022, 0.023-0.037, 0.038-0.297, or ≥0.30 ng/
mL), and rice eating in the past 30 days (yes or no). Data
regarding disease history were also collected. Hyperten-
sion was defined as systolic blood pressure ≥140 mmHg
and diastolic blood pressure ≥ 90 mmHg, the use of
antihypertensive drugs or previous physician-diagnosed
hypertension. Diabetes was defined as a fasting plasma
glucose level ≥6.99 mmol/L, a nonfasting plasma glucose
level ≥ 11.1 mmol/L, current insulin use or a prior phys-
ician diagnosis of diabetes. Body mass index (BMI) was
calculated by dividing measured weight in kilograms by
measured height in meters squared and was categorized
into four groups- underweight (<18.5 kg/m2), normal
weight (18.5–24.9 kg/m2), overweight (25–29.9 kg/m2),
and obese (≥30.0 kg/m2).
Statistical analysis
To account for the complex sampling design, weighted
estimates of the population parameters were com-
puted using the NHANES Analytic and Reporting
Guidelines. All the analyses were performed using the
PROC SURVEY procedures in SAS 9.3 (SAS Institute,
Cary, NC, USA).
The blood cadmium levels were log transformed to im-
prove normality, and the geometric mean was calculated.
Smoking-adjusted means (or least square means) were
predicted values from a multiple regression equation, by
treating never smokers as the reference group using the
“LS means” option of the “PROC SURVEYREG” proced-
ure. Significant differences in the demographic and clin-
ical variables were evaluated using the chi-square test
and tests for trends to compare variables across ordered
categories of blood cadmium levels. We divided the
study population by blood cadmium quartiles (≤0.3,
0.3–0.4, 0.4–0.6, and >0.6 μg/L). A Cox proportional
hazards regression using “PHREG” procedure was con-
ducted to evaluate the association of AD–related mor-
tality with blood cadmium quartiles. We calculated the
hazard ratio (HR) for the risk of AD mortality with
respect to blood cadmium quartiles by comparing the
first quartile, the 95 % confidence intervals (CIs), and
the p-values for the trends. In the hazard model, age
and age square were treated as continuous variables,
and the analyses were adjusted for potential con-
founders: Model 1 was adjusted for age, age square,
sex, ethnicity, education, family income, smoking, and
serum cotinine, and Model 2 was further adjusted for
rice eating, BMI, and history of diabetes and hyperten-
sion. We also generated the Kaplan-Meyer curves using
the ‘DIRADJ’ option to obtain the direct adjusted sur-
vival curve by averaging the predicted survival func-
tions for baseline covariates.
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Table 1 Geometric mean (SE) blood cadmium levels of the participants (n = 4064) at baseline with results grouped by demographic
characteristics
No. Unadjusted mean (SE) p-value Smoking-adjusteda mean (SE) p-value
Age, y
60–69 1852 0.48 (0.01) 0.002 0.45 (0.01) <.0001
70–79 1354 0.49 (0.01) 0.51 (0.01)
80–89 858 0.52 (0.01) 0.58 (0.01)
Gender
Male 2024 0.48 (0.01) 0.002 0.44 (0.01) <.0001
Female 2040 0.50 (0.01) 0.54 (0.01)
Ethnicity
White 2388 0.49 (0.01) 0.017 0.49 (0.01) 0.001
Black 603 0.47 (0.01) 0.46 (0.01)
Hispanic 972 0.48 (0.01) 0.48 (0.02)
Other 101 0.62 (0.04) 0.63 (0.04)
Education
Less than high school 1678 0.52 (0.01) <.0001 0.54 (0.01) <.0001
High school 956 0.48 (0.01) 0.50 (0.01)
College or higher 1430 0.46 (0.01) 0.46 (0.01)
Family income
Less than $20,000 1689 0.54 (0.01) <.0001 0.54 (0.01) <.0001
$20,000 or more 2375 0.46 (0.01) 0.47 (0.01)
Serum cotinine, ng/mL
Q1 (≤0.022) 1037 0.41 (0.01) <.0001 0.46 (0.01) <.0001
Q2 (0.023–0.037) 1013 0.45 (0.01) 0.50 (0.01)
Q3 (0.038–0.297) 1028 0.42 (0.01) 0.48 (0.01)
Q4 (≥0.30) 986 0.75 (0.02) 0.54 (0.02)
Rice eating
Yes 864 0.49 (0.01) 0.317 0.50 (0.01) 0.449
No 3200 0.48 (0.02) 0.49 (0.01)
Body mass index, kg/m2
< 18.5 51 0.67 (0.05) <.0001 0.54 (0.04) <.0001
18.5–24.9 1106 0.56 (0.02) 0.54 (0.01)
25.0–29.9 1646 0.47 (0.01) 0.48 (0.01)
≥ 30 1261 0.45 (0.01) 0.47 (0.01)
Diabetes
Yes 876 0.45 (0.01) 0.003 0.45 (0.01) 0.003
No 3188 0.50 (0.01) 0.50 (0.01)
Hypertension
Yes 2760 0.49 (0.01) 0.568 0.51 (0.01) 0.003
No 1304 0.50 (0.01) 0.47 (0.01)
Cigarette smoking
Current smoker 494 1.14 (0.03) <.0001
Former smoker 1676 0.49 (0.01)
Never smoker 1894 0.39 (0.00)
aSmoking-adjusted mean levels were calculated by adjusting cigarette smoking status (current, former, and never smoker), in which never smokers were treated
as the reference group
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Results
Table 1 presents the mean blood cadmium level among
older adults by demographic characteristics. For the un-
adjusted mean distribution, older adults with higher blood
cadmium levels were more likely to be 60–69 years old, fe-
males, and other ethnicity, to have low income, less educa-
tion, and high serum cotinine levels, to be underweight,
and to exhibit no history of diabetes and hypertension,
and to be current smokers. The smoking-adjusted mean
cadmium levels showed similar patterns, except for higher
cadmium levels among subjects at 80–89 years old and
with history of hypertension.
Table 2 presents the HRs for AD–related mortality by
blood cadmium quartiles at baseline. After multivariable
adjustment, older adults in the highest cadmium quartile
exhibited an adjusted HR for AD mortality of 3.76 (95 %
CI = 1.43–9.93) in Model 1 and 3.38 (95 % CI = 1.38–
10.59) in Model 2, compared to those in the lowest cad-
mium quartile. In the Kaplan–Meier survival curves for
cumulative AD mortality (Fig. 1), higher levels of blood
cadmium showed marginally significant association with
increased mortality at baseline and in adults older than
60 years of age (p = 0.0684).
Discussion
We found that blood cadmium levels were significantly
associated with AD-related mortality among older
adults. Compared with participants who exhibited low
blood cadmium levels (≤0.3 μg/L), those with high cad-
mium levels (>0.6 μg/L) exhibited a 3.83-fold increased
risk of AD mortality, and significant dose–response rela-
tionships were observed for the risk of AD mortality.
AD is the most common type of dementia and be-
comes a major public health issue as the population
ages. The World Alzheimer Report 2014 revealed that
the number of people with dementia was estimated at 44
million, posing a substantial portion of global burden of
disease [20]. Although AD pathogenesis is multifactorial
and complex, studies suggest that toxic metals may rep-
resent a possible cause of AD [21–23]. There is growing
evidence that cadmium plays a role in the accumulation
of Aβ plaques and tau protein [24–26], as the main
pathological components of AD [1, 2]. Syme and Viles
(2006) found that Cd(II) caused the 1H NMR chemical
shift of the Val12 γCH3 protons in Aβ (1–16) that is
similar to that observed for Zn(II), which is known to be
an important inducer of amyloid production [25, 27]. In
a mouse model, relative to the control group, the
cadmium-treated group exhibited lowered learning abil-
ity and reduced expression of α-secretase, soluble APPα
and the neutral endopeptidase protein in the hippocam-
pus and cerebral cortex, thereby contributing to the
increases in the Aβ1-42 levels [28]. A recent study re-
vealed the interaction between Cd(II) and the Aβ1-42
peptide; Cd(II) decreased Aβ1-42 peptide channel
activity and turnover until the channel activity is com-
pletely abrogated [29]. Jiang et al. (2007) added evi-
dence of the involvement of Cd(II) in the tau tangle
Fig. 1 Kaplan–Meier survival curves for cumulative AD mortality
according to blood cadmium quartile at baseline. Cadmium quartiles:
Quartile 1: ≤ 0.3 μg/L; Quartile 2: 0.3–0.4 μg/L; Quartile 3: 0.4–0.6 μg/L;
Quartile 4: > 0.6 μg/L. Quartiles 2 and 3 are almost indistinguishable
Table 2 Hazard ratio (HR) for AD mortality by blood cadmium level at baseline
Event
no. (%)
Crude HR (95 % CIs) Adjusted HR (95 % CIs)a
Blood cadmium level Model 1 Model 2
Cadmium quartile, μg/L
Quartile 1 (≤0.3) 7 (0.7) 1.00 (ref) 1.00 (ref) 1.00 (ref)
Quartile 2 (0.3–0.4) 11 (1.4) 1.80 (0.55–5.92) 1.83 (0.57–5.86) 1.81 (0.54–6.07)
Quartile 3 (0.4–0.6) 15 (1.3) 1.99 (0.83–4.75) 1.86 (0.74–4.70) 1.88 (0.73–4.85)
Quartile 4 (>0.6) 18 (1.6) 2.66 (1.06–6.63) 3.76 (1.43–9.93) 3.83 (1.38–10.59)
p value for trend 0.228 0.068 0.068
Note: CIs = confidence intervals, HR = hazard ratio, ref = reference
aModel 1: Adjusted for age, age square, gender, ethnicity, education, family income, smoking, and serum cotinine level
Model 2: Further adjusted for rice eating, body mass index, diabetes, and hypertension
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formation through the acceleration or induction of the
aggregation of Alzheimer's tau peptide R3 [24].
Few human studies have supported the possible link of
cadmium with AD pathogenesis. Compared with normal
subjects, elevated cadmium levels in the liver, plasma,
and brain tissue [15–17] have been detected among AD
patients. Our study, which demonstrated that the low
blood cadmium levels currently observed in the US gen-
eral population are associated with an increased risk for
AD mortality, is consistent with the limited evidence.
Admittedly, the reason for the observed association re-
mains uncertain, but the potential relevance of cadmium
to amyloid and tau filament formation may help explain
the increased risk for developing AD.
The findings from the present study should be inter-
preted with caution. The most important limitation was
that only a single blood cadmium measurement per pa-
tient was available. After cadmium exposure, it binds to
metallothionein and accumulates in the human body,
particularly in the kidney [30, 31]. Biomonitoring of cad-
mium exposure for environmentally exposed populations
is usually conducted by detecting cadmium levels in the
urine and blood. Urine cadmium level is a reflection of
body burden (mainly kidney) with a half-life of 11.6 years
[31]. In contrast, blood cadmium, a marker of ongoing
exposure, reflects recent uptake. Its half-lives ranged
from three to four months in the fast compartment and
from 7.4 to 16.0 years in the slow component [32]. Blood
cadmium levels used in the blood are dependent on daily
exposure and primarily reflect recent exposure. Thus,
we could not completely assess cadmium exposure. In
addition, we relied only on death certificates obtained
from the 1999–2004 NHANES Linked Mortality File
and did not have information on the morbidity incident
events. AD and other dementias were rarely reported as
the primary cause of death [33, 34]. This is potentially
because death certificates often list the immediate cause
of death, rather than listing dementia as an underlying
cause. In one series of AD cases, only 20.8 %–36 % of the
total AD patients stated AD as the cause of death [33, 34].
Finally, we adjusted for several variables in the statistical
model; because of the observational nature of this investi-
gation, we cannot rule out the possibility of residual con-
founding effects by unmeasured confounders. Moreover,
maximum 100 months follow up period is generally too
short for the population without AD to compare the sur-
vival from AD deaths, which is reflected in the very high
survival rate above 0.97 even in the highest category of the
bold cadmium subgroups.
Conclusion
This study showed a significant association between
blood cadmium levels and AD mortality among older
adults in the US. Although further studies are necessary
to clarify the observed association, our findings support
the potential relevance of cadmium to AD pathogenesis
and suggest that the elevation of blood cadmium levels
may present an important predictive marker of increased
AD mortality risk. Thus, efforts to reduce cadmium-
related disease risk from environmental exposure to cad-
mium should be continued.
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